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Amyotrophic lateral sclerosis (ALS) is a lethal neurodegenerative disorder characterized by the selective degeneration
of defined subgroups of motoneuron in the brainstem, spinal cord and motor cortex with signature hallmarks of
mitochondrial Ca2+ overload, free radical damage, excitotoxicity and impaired axonal transport. Although intracellular
disruptions of cytosolic and mitochondrial calcium, and in particular low cytosolic calcium ([Ca2+]c) buffering and a
strong interaction between metabolic mechanisms and [Ca2+]i have been identified predominantly in motoneuron
impairment, the causes of these disruptions are unknown. The existing evidence suggests that the mutant superoxide
dismutase1 (mtSOD1)-mediated toxicity in ALS acts through mitochondria, and that alteration in cytosolic and
mitochondria-ER microdomain calcium accumulation are critical to the neurodegenerative process. Furthermore,
chronic excitotoxcity mediated by Ca2+-permeable AMPA and NMDA receptors seems to initiate vicious cycle of
intracellular calcium dysregulation which leads to toxic Ca2+ overload and thereby selective neurodegeneration.
Recent advancement in the experimental analysis of calcium signals with high spatiotemporal precision has
allowed investigations of calcium regulation in-vivo and in-vitro in different cell types, in particular selectively
vulnerable/resistant cell types in different animal models of this motoneuron disease. This review provides an
overview of latest advances in this field, and focuses on details of what has been learned about disrupted Ca2+
homeostasis and mitochondrial degeneration. It further emphasizes the critical role of mitochondria in preventing
apoptosis by acting as a Ca2+ buffers, especially in motoneurons, in pathophysiological conditions such as ALS.
Keywords: Amyotrophic lateral sclerosis (ALS), Motoneuron, Calcium dysregulation, Mitochondria, ER-mitochondria
calcium cycle (ERMCC), Selective vulnerability, Calcium buffering, Multifactorial disease, Multidrug therapyIntroduction
Amyotrophic lateral sclerosis (ALS) is an incurable, adult-
onset, deadly neurodegenerative disorder distinguished by
the progressive degeneration of a defined motoneuron
(MN) population in the brain stem, spinal cord and motor
cortex. ALS leads to paralysis, atrophy and death within
5 years [1]. Currently, there are no effective drug formula-
tions for cures and riluzole is the only FDA approved
treatment available for this devastating disease. TheCorrespondence: manoj.jaiswal.ctr@usuhs.edu
1Center for Neuroscience and Regenerative Medicine, 4301 Jones Bridge
Road, 20814 Bethesda, MD, USA
2Department of Anatomy, Physiology and Genetics, School of Medicine,
USUHS, 4301 Jones Bridge Road, 20814 Bethesda, MD, USA
© 2014 Jaiswal; licensee BioMed Central Ltd. T
Commons Attribution License (http://creativec
reproduction in any medium, provided the or
Dedication waiver (http://creativecommons.or
unless otherwise stated.majority of ALS cases are sporadic, but ~10% of ALS
cases are familial ALS (fALS). About 20% of these familial
cases are caused by dominantly inherited mutations in the
gene encoding the enzyme Cu/Zn-superoxide dismutase
(SOD1) and are the most common [2]. Mutations in a
number of other genes also cause familial ALS; including
mutations in autosomal dominant familial MN disease
include fALS types 3 [3], 5 [4], 6 or FUS gene [5,6], 7 [7],
8 [8], 9 or ANG gene [9], 10 or TDP-43 (TARDBP gene)
[10-12], 11 or Figure four gene [13], NF-H gene [14],
DAO gene [15], X-linked [16], C90RF72 [17-19], alsin [20]
and MND with FTD [21].
Unfortunately, the discovery of these mutant genes
has not yet advanced into useful ALS model organisms,his is an Open Access article distributed under the terms of the Creative
ommons.org/licenses/by/2.0), which permits unrestricted use, distribution, and
iginal work is properly credited. The Creative Commons Public Domain
g/publicdomain/zero/1.0/) applies to the data made available in this article,
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conducted on mutant SOD1 cells, rodents or on patients
(both familial and sporadic). Although the process of MN
degeneration both in sporadic and familial forms is still
little understood, it is generally agreed that there are cell-
specific features, particularly impaired uptake of Ca2+ into
mitochondria and low content of Ca2+ binding proteins
which modulate physiological as well as pathophysio-
logical processes and may render MNs selectively vulner-
able to degeneration [22-25]. In both SOD1-mediated and
sporadic sALS, reports demonstrate that mitochondrial
alterations, including morphological changes, enhanced
activity of complexes I, III, and IV, and increased reactive
oxygen species (ROS) generation, are key factors in its
pathogenesis [8,26-30]. These factors are further exacer-
bated by observations indicating that the impaired spinal
cord and vulnerable spinal cord neurons trigger the func-
tional decline of MNs in neighboring regions, leading to
the onset of pathology in ALS [31-34]. The breakdown of
mitochondrial membrane potential (ΔΨm), excitotoxic
stimulation of AMPA/kainite receptors and age associated
MN damage reported by several groups may also be a
factor to ALS pathogenesis [35-38].
Impaired intracellular Ca2+ homeostasis, rather than
direct mitochondrial disruption, is supported by observa-
tions that neurons lost early in the disease progression
have intrinsically poor cytoplasmic Ca2+ buffering capabil-
ities, due to the absence of Ca2+ binding proteins such as
calbindin D28K (CB-D28K) and parvalbumin (PV) [22,36].
These findings are in agreement with observations that
low cytosolic Ca2+ buffering ability acts as a primary risk
factor for MN deterioration, while increases in cytosolic
Ca2+ buffering capacity protects vulnerable MNs from
degeneration, both in-vitro and in-vivo [25,36,39,40]. In
addition to the mechanisms of Ca2+ toxicity present in
most cell types, there are several other characteristics of
neurons that make them especially vulnerable. Disturbances
of glutamate-mediated neurotransmission and the sub-
sequent glutamate release triggered by Ca2+ entry [41]
increase extracellular glutamate levels leading to excito-
toxicity. This problem is further compounded by reduced
glial glutamate uptake caused by oxidative damage to exci-
tatory amino acid transporter 2 (EAAT2) [42]. Studies of
fALS in cell lines and in various mouse models that in-
duce Ca2+ disturbance via the inhibition of glial glutamate
transport by mtSOD1 yield phenotypes similar to effects
proposed in sALS [43]. In addition, in cell culture experi-
ments, partial protection was also obtained by treatment
with the Ca2+channel-blocker nifedipine, implicating Ca2+
entry through voltage-gated Ca2+ channels in mediating
the toxicity of mtSOD1G93A in MNs [44]. In addition to
damaging the cell of origin, ROS generated in MNs can
cross the plasma membrane and damage glutamate trans-
porters in neighboring astrocytes [41,45]. Further evidencealso indicates that the patients with minor SOD1 muta-
tions had the shortest disease durations. In other words,
an accelerated disease course is found for the mutants
that are more functionally impaired. Since hydrogen
peroxide plays an essential role in the formation of
SOD1 monomers, dissociation of the dimeric SOD1
molecule monomers should be as essential important
process for APS pathogenesis [46].
However, in ALS pathology, the cause of dysfunction
has become highly contentious after latest discoveries
where ALS astrocytes were shown to secrete substances
that are selectively toxic to MNs [47,48]. This means that
multiple cell types are involved in the disease process. By
adding or deleting mtSOD1 in specific cell types e.g. astro-
cytes [49,50], microglia [51], schwann cells [52], motor
neurons [53] and fibroblast [54] it is possible to influence
the disease. Nonetheless, MNs are the cells that directly
cause the loss of muscle and limb movement. It is shown
that mtSOD1 expressed solely in MNs is sufficient to kick
off the disease, although disease progression is slow
compared to ubiquitous expression of mtSOD1 [53]. In
patients, MNs in the motor cortex, HMNs and FMNs of
brain stem and spinal cord undergo cell death selectively.
There are a number of hypothesis that explain cell type se-
lectivity, including the extraordinary long axons, the large
soma and the poor intracellular calcium buffering capacity
and excitotoxicity. It is the latter hypothesis that shall be
elaborated on in this review, the only mechanism proved
to play a role in patients. Calcium, which causes neuronal
death in excitotoxicity, can originate from either the extra-
cellular space or from intracellular stores. In general rest-
ing calcium in the extracellular space is ~ 3–4 orders of
magnitude higher than in the intracellular stores [55]. As
reported previously, MNs are excited by glutamate from
the pre-synaptic neuron that binds to glutamate receptors
on the postsynaptic MN, which are, among others, the
AMPA receptors (AMPAR). The AMPAR found on MNs
are mainly calcium permeable in vitro and in-vivo [56-59],
which may explain the selective vulnerability of MNs to
excitotoxic cell death. In addition, extracellular calcium
entry via these calcium permeable AMPAR is responsible
for selective MN death, as MN death is inhibited by se-
lective blockers of calcium permeable AMPAR [57,58].
Also, electrophysiological experiments showed that the
AMPAR receptors of MNs had a lower rectification index
and a higher relative calcium permeability ratio than other
neurons [59]. In conclusion, MNs express calcium per-
meable AMPAR receptors, which could partially explain
their pronounced and selective vulnerability to excitotoxic
insults [59]. Further explanation for selective MN vulner-
ability in this cell type has to deal with the increased
amount of intracellular calcium. Studies into the calcium
homeostasis in MNs have shown a diminished calcium
buffering capacity distinguishing ALS-vulnerable from
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and brain stem MNs in mice display a low endogenous cal-
cium buffering capacity as demonstrated by patch clamp
and microfluorometirc calcium measurements [60,61]. In
addition, ALS-resistant oculomotor neurons contain a
larger calcium buffering capacity than ALS-vulnerable
MNs, as measured by similar microfluorometirc calcium
measurements [62].
The kinetics of calcium signals in MNs are shaped by
multiple mechanisms including Ca2+ influx, Ca2+ uptake
and release phenomenon, MN specific Ca2+ buffering and
extrusion across cellular membrane and microdomains
in vicinity [63,64]. Over the past decade, there has been
an increased understanding of local communications
between Ca2+ microdomains and its upstream and
downstream target signaling pathways. In particular,
an impaired interaction between calcium signaling and
mitochondrial processes has been identified as one
cellular factor contributing to neurodegenerative pro-
cesses like those found in motoneuron diseases. In
addition, previous studies also indicate the importance
of calcium and mitochondria for normal physiological
function of MNs [62,65]. Under pathophysiological
conditions, low [Ca2+]i buffering and a robust interaction
between metabolic processess and [Ca2+]i have been
related with selective and severe MN damage resulting
from excitotoxic stress and disruptions of cellular and
mitochondrial Ca2+ homeostasis [66,67]. Considering the
prime participation of mitochondria not only in calcium
homeostasis directly but also in the energy transduction
(to operate other Ca2+ clearing mechanisms) and in
enacting apoptosis, this aspect of cellular function is of
immense importance.
The influence of mitochondrial dysfunction on
intracellular Ca2+ homeostasis and its role in MN
death are fascinating issues that warrant in depth de-
bate. Despite rigorous research, since description of
ALS by Charcot ~ 130 years ago, the cellular and mo-
lecular abnormalities, which lead to loss of specific
MNs, are still dodging the scientific community. Obvi-
ously, unraveling the connecting association between
mitochondrial dysfunction, calcium dysregulation, and
neuronal demise is vital for the understanding of ALS
pathogenesis. The aim of this review is to discuss and
determine the role of mtSOD1 toxicity in cellular Ca2+
homeostasis and mitochondrial dysfunction in MNs of
ALS. This review will focus on what has been learned
about motoneuron specific calcium dysregulation and
perturbed cellular calcium homestasis in ALS from
genetically modified animals and cell culture models.
Taken together, this review proposes an intregative
view, describing mechanisms and critical elements of the
pathology of mtSOD1-mediated motoneuron degeneration
in ALS.Review
Disease mechanism in amyotrophic lateral sclerosis
Many pathophysiological mechanisms have been sug-
gested to play a role in the etiology of ALS. Corresponding
to clinical features, ALS is characterized by a progressive
loss of spinal, brains stem and cortical MNs. MN damage
as a result of oxidative stress and excitotoxicity is one of
the key hypothesis in ALS etiology. The present evidence
also supports the hypothesis of mitochondrial dysfunction
acting with oxidative stress to cause neurodegeneration
via apoptotic mechanisms. Oxidative stress is also linked
with other suggested disease mechanisms such as exci-
totoxicity causing an increase in [Ca2+]i, which subse-
quentially leads to increased nitric oxide formation.
Peroxynitrite, produced by the reaction of superoxide
anions and nitric oxide, can consequently lead to oxida-
tive disruption [42]. Glutamate excitotoxicity is another
mechanism implicated in ALS pathogenesis through
disruption of [Ca2+]i homeostasis and free radical pro-
duction. For example, in human ALS (hALS), overex-
pression of glutamatergic synapses leading to excessive
Ca2+ influx has been linked with MN degeneration [68].
The oxidative stress manifested in ALS might also prop
up increased excitotoxicity, as glutamate transporters
are predominantly susceptible to disruption by oxidants,
and oxidative modifications to the transporters have been
reported in ALS and the mtSOD1 mouse model [69]. The
roles of individual cellular domains at the organelle level
suggest that high calcium buffering enhances MNs vulner-
ability [70,71]. In summary, ALS comprises the interplay
of numerous mechanisms from initiation and spread of
MN cell death by mitochondrial dysfunction and/or by
enhanced MN excitability by intracellular calcium over-
load. Therefore the etiology of the disease is most likely to
be multifactorial [72,73]. This article will focus on and
further discuss the hypothesis and key mechanism that
have been most influential in the present and past decade
of ALS research.
Oxidative stress sensitivity and mitochondrial dysfunction
Oxidative stress occurs from an imbalance between the
production of ROS and the ability of the system to remove
ROS or repair the damage caused because of it, and to
reinstate the existing reducing ambiance [68]. Oxidative
stress and mitochondrial dysfunction are implicated in the
pathogenesis of both normal aging and neurodegenerative
diseases. There is ongoing debate as to whether oxidative
stress is a primary cause of degeneration or it is merely an
end result of some other toxic insult. Although oxidative
stress is implausible to be the solitary cause of disease
initiation, in several cases it may be enhance vulnerability
of homeostatic control mechanisms from handling with a
toxic insult into a vicious cycle of cellular insults that re-
sults in MN degeneration. MN damage as a consequence
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ALS. A number of studies have established the existence
of elevated oxidative metabolism in ALS, for example
finding of increased biochemical markers of oxidative
injury in post-mortem samples from ALS patients [38].
Free radical scavenging proteins like SOD1, mitochondrial
manganese SOD (SOD2), catalase, and cytochrome c can
neutralize free radicals but can not prevent cellular dam-
age by ROS [38,72]. Increased .OH generation may occur
as an end result of either enhanced peroxidase activity or
decreased Cu-binding affinity of mtSOD1. mtSOD1 trans-
genic (Tg) mice show elevated levels of protein and
lipid oxidation at both pre- and post-symptomatic
stages of MN dysfunction [74,75]. Oxidative stress is
also associated with many other proposed disease
mechanisms such as excitotoxicity and axonal trans-
port defects [76-80]. Studies suggest that ROS gener-
ated in MNs can cross the plasma membrane to
produce oxidative damage to glutamate transporters in
neighboring astrocytes via the excitotoxic stimulation of
AMPA/kainate receptors, followed by locally restricted
excitotoxicity. This initiates a vicious cycle of MN overac-
tivation causing damage, which in turn further activates
MNs [37,46,62].
Morphological and ultrastructural abnormalities observed
in mitochondria of both, sporadic and familial forms of
ALS point towards a crucial involvement of mitochondria
in ALS [81-84]. Localization and aggregates of SOD1 in
mitochondria of transgenic mouse models were shown
previously [85-87]. There are now several observations
suggest that mitochondria play a crucial role in disturbing
energy metabolism by predisposing calcium-mediated
excitotoxicity, leading to ROS generation and initiation of
the apoptotic pathway, thereby jeopardizing cell function
and normal cellular metabolism [88,89]. Defects in mito-
chondrial function have been found in fALS and some
sALS by histopathological observations of mitochondrial
swelling and vacuolization in ALS transgenic mouse
models and in ALS patients [28,30,31,39,62,90]; Figure 1A.
Morphological abnormalities were not only confined to
CNS, but were also found in skeletal muscles, intra-
muscular nerve fibers and proximal horns of the spinal
cord [91-93]. Recently, in a SOD1-transfected cell cul-
ture model of MN disease, our laboratory has shown
impairement of mitochondrial calcium handling and
impaired cross-talk between mitochondria-endoplasmic
reticulum (ER) microdomains [94]; Figure 1B-D. Many
other studies have recently focused on mitochondrial
dysfunction, specifically on the increased activity of the
mitochondrial respiratory chain necessary for ATP syn-
thesis, resulting in an increased ROS production. Fur-
thermore, the excessive electron transport chain activity
can deplete energy stores, resulting in the loss of in-
tegrity of neuronal cell membranes and leaving thempermeable to ions and water which can cause damage.
Deficits in the activities of complex I and complex IV, as a
result of mutations in mitochondrial DNA, have been
identified in the skeletal muscles and spinal cord of sALS
patients [33,95,96].
The query of whether changes in the mitochondrial
genome can cause variations in mitochondrial function
has been addressed by transferring mitochondrial DNA
from ALS subjects to mitochondrial DNA-depleted human
neuroblastoma cells. This manipulation resulted in anom-
alous electron transport chain function, increases in the
activity of free radical scavenging enzymes, disturbed Ca2+
homeostasis and altered mitochondrial structure, suggest-
ing a pathophysiological role for mitochondrial DNA
mutations in different forms of ALS [94,97]. A striking
recent set of publications provides evidence that mtSOD1
might disrupt the association of respiratory complex IV
(cytochrome c) with the inner mitochondrial membrane,
thus obstructing the mitochondrial respiratory system.
Cultured MNs expressing mtSOD1 and MNs in ex-vivo
brain slices where respiratory chain complex IV was
blocked by cyanide or azide also shows mitochondrial
involvement [98-100].
The major question of whether mitochondrial anomalies
are involved in the disease progression or simply a deriva-
tive of neuronal degeneration is still far from over. Patho-
logical features like the occurrence of membrane-bound
vacuoles in MNs in Tg mice expressing G93A or G37R
suggest that mitochondrial alterations are an early conse-
quence eliciting the beginning of the disease, instead of
merely a derivative of neuronal degeneration [101,102].
Mitochondrial vacuolization occurs by detachment of the
outer membrane from the inner membrane and increase
of the intermembrane space, confirmed by biomarkers
studies for mitochondrial compartments. After mem-
brane expansion, mature vacuoles form which leads to
the inner membrane disintegrations [103,104]. A recent
publication demonstrates the localization of a signifi-
cant fraction of SOD1 in intermitochondrial space
thereby causing toxicity. Inhibition of mitochondrial re-
spiratory metabolism is reported in Tg ALS mice models
[105,106]. Certainly, MNs are highly susceptible to
mitochondrial damage. Studies using mitochondrial re-
spiratory chain inhibition by cyanide and azide result in
selective MN death, which can be counteracted by ROS
scavengers and AMPAR blockers [62,107]. Furthermore,
ALS-like symptoms can be induced by deletion of
vascular endothelial-cell growth factor (VEGF) that
eliminates the ability to respond to tissue mild and
chronic hypoxia [108-110]. Cross-breeding these mice
with the mtSOD1 severely enhanced MN degeneration,
while treatment of SOD1-Tg mice with VEGF hindered
progression of disease symptoms and extend mice
survival [62,111-117].
Figure 1 Mitochondrial structure of motor neurons in mutant SOD1 transgenic mice and calcium load in microdomains in a cell
culture model of motoneuron disease. (A) a, Shows abnormalities like dilated cristae (asterisk) and leaking outer membrane (indicated with
arrow) in mitochondrion. (A) b, Swollen dendritic mitochondria with dilated and disorganized cristae (adapted from ref. 31). (B-D) The simultaneous
measurement of cytosolic calcium (Fura-2) and mitochondrial calcium (Rhod-2) concentrations in WT and G93A transfected SH-SY5Y cells during
FCCP-evoked mitochondrial Ca2+ release. (B) The kinetic profile of the FCCP-evoked Ca2+ release in the WT transfected SH-SY5Y neuroblastoma cells;
the cytosolic (Error bar green, black square trace) and mitochondrial (Error bar red, black circle trace) compartment were measured simultaneously. The
trace represents the mean of 5 cells in focus stimulated with 2 μM FCCP. (C) The corresponding kinetic profile of the FCCP-evoked Ca2+ release in the
G93A transfected SH-SY5Y neuroblastoma cells; the cytosolic (Error bar green, black square trace) and mitochondrial (Error bar red, black circle trace)
compartment were measured simultaneously. The trace represents the mean of 5 cells in focus stimulated with 2 μM FCCP. FCCP-evoked [Ca2+]mito
signals were smaller in amplitude and exhibited slower kinetics in G93A transfected SH-SY5Y cells compared to WT transfected cells and were altered
from [Ca2+]i efflux. (D) A bar diagram of the cytosolic (green bar) and mitochondrial (red bar) fluorescence signals (F/F0) from WT (F/F0 = 0.1569 ± 0.0235
for [Ca2+]i and F/F0 =−0.1069 ± 0.0181 for [Ca2+] mito; hollow; N = 5, n = 17) and G93A (F/F0 = 0.1008 ± 0.0248 for [Ca2+]i and F/F0 =−0.0486 ± 0.0043 for
[Ca2+]mito; striped pattern, N = 4; n = 17) transfected SH-SY5Y neuroblastoma cells. Values represent means ± SD, **p< 0.001. N =Number of experiments;
n = Number of cells (adapted from ref. 94).
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motoneurons and its impact on selective motoneuron
vulnerability in amyotrophic lateral sclerosis
Several groups have reported that, the disruption of
intracellular Ca2+ homeostasis plays a prominent role in
the etiology of ALS. The involvement of Ca2+ as a risk
factor was suggested by the observation that Ca2+-binding
proteins such as CB-D28k and PV were absent in MN pop-
ulations lost early in ALS. In contrast, MNs less prone to
damage expressed markedly higher levels of calcium-
binding proteins CB-D28k and/or PV [22,62], and were
relatively insensitive to mitochondrial calcium buffering.
In dorsal vagal neurons, which contain an abundance ofCa2+ sequestering proteins [118], the delay in the decay
time constant (τ) of Ca2+ transients (FCCP influx) is not
caused by mitochondrial permeability. This observation
identified a low cytosolic Ca2+ buffering capacity as an
important risk factor for MN degeneration. Data from
different groups shows that the vulnerable populations
of MNs display low endogenous calcium buffering cap-
acity [119], due to low expression levels of Ca2+-buffering
proteins. Although potentially essential under physio-
logical conditions, as it allows for rapid Ca2+ transients
relaxation times during high frequency rhythmic activity,
these characteristics make MNs more susceptible to an
excessive influx of Ca2+ ions. This susceptibility increases
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cascades and related cellular damages [62,119]. Another
argument in favor of this hypothesis is that high concen-
trations of mobile buffers accelerate the distribution of
local Ca2+ gradients by a mechanism known as buffering
diffusion (Figure 2A, B). According to this concept, underFigure 2 Ca2+ homeostasis and its correlation with weakly and strong
pathophysiological conditions. (A) The Ca2+ buffering capacity (KS) of a
calculated by using the ‘added buffer’ approach by linear one-compartmen
amount of endogenous buffer (S; denotes Ca2+-binding proteins), the amo
Ca2+ across cellular membranes. KB indicates the buffer capacity of the exo
buffered MNs. The amplitude of Ca2+ transients is several times larger in w
cells (e.g. oculomotor neurons), and the recovery time is significantly accele
mitochondria to higher Ca2+ loads compared to high-buffered cells. Under no
NMDA and AMPA receptor channels along with VDCC with high glutamate r
intracellular calcium that can be buffered by the cell. In ALS disorder, the glut
high Ca2+ loads; increase the risk for mitochondrial damage. This triggers mito
inhibit glial EAAT2 function. This leads to further increase in glutamate concen
which contributes to the selective vulnerability of MNs in ALS. Low cytosolic C
subcellular domains around influx sites (red), and thus facilitates the interactio
mitochondria (modified from refs. [62-63,73,94,118]).pathophysiological conditions, differential buffering reflects
a basic diversity in the spatio-temporal organization of Ca2+
signaling rather than a singular difference in single cellular
parameter [120-122]. Likewise, an increase in [Ca2+]i buff-
ering capacity could defend vulnerable MNs and protect
from degeneration both in vitro and in-vivo [25,123].ly buffered motoneurons under physiological and
cell, reflecting relative fraction of bound versus free Ca2+, can be
t model. The recovery time of [Ca2+]i elevations (τ) depends on the
unt of exogenous buffer (B; i.e. Fura-2) and the transport rate (γ) of
genous buffer (i.e. Fura-2). (B) Ca2+ homeostasis in weakly and strongly
eakly buffered cells (e.g. HMNS and SMNs) than in strongly buffered
rated (τ). (C) Low Ca2+ buffering in ALS-vulnerable HMNs exposes
rmal physiological conditions the neurotransmitter opens glutamate,
elease and reuptake by EAAT1 and EAAT2. This results in a small rise in
amate receptor channels possess high calcium conductivity and thereby
chondrial production of reactive oxygen species (ROS), which then
trations in the synapse and further rises in postsynaptic calcium levels
a2+ buffering capacity promotes Ca2+ accumulation and formation of
n of elevated calcium levels with intracellular organelles such as
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can protect cells from dysfunction and degeneration, our
group performed Ca2+ imaging studies following a
depolarization stimulus (60 mM K+) in primary neuronal
cells obtained from mice cortex at E18 expressing low
and high CB-D28k. Results show that indeed CB-D28k
buffer [Ca2+]i where low CB-D28k transfected neuronal
cells display a significant (~2 times) reduction in the
peak amplitude of the sustained [Ca2+]i increase compare
to high CB-D28k transfected neuronal cells (data not
shown). τ in CB-D28k transfected cells is also slower (~60s)
compared to non-transfected cells where baseline recovery
time is ~30-35 s while showing little differences in the area
under the time - concentration curve (AUC). This ob-
servation is in good agreement with the ∁low buffering
hypothesis” which states that low buffer capacity allows
for rapid Ca2+ dynamics during physiological activity,
but represents a significant risk factor during ALS-related
MN disease [124]. The observation of high cytosolic buff-
ering capacity in selectively resistant MNs is consistent
with earlier immunocytochemical studies of endogenous
calcium buffering proteins. Moreover, in-vitro cell culture
models have shown that elevated [Ca2+]i buffer concentra-
tion reduces ALS specific MN damage providing further
support in favor of the notion that increased buffer
concentrations create beneficial protection [125]. The
low Ca2+ buffering properties synergize with a high
AMPA/kainate current density to clarify the suscepti-
bility of MNs to increased stimulation by glutamate
and associated Ca2+ influx [59,126]. Earlier observation
also indicates interactions of mitochondrial proteins
e.g. VAPBP56S and PTPIP51 implicated in regulating
calcium homestasis [127,128].
In the absence of adequate cytoplasmic buffering, or
in cases where the existing cytoplasmic buffering system
is overwhelmed, there is a shift in mitochondrial Ca2+
uptake from a beneficial physiological regulatory mech-
anism to a possibly detrimental process leading towards
MNs death. In this process MNs death is clearly Ca2+
dependent. The downstream mechanism that links the
rise in [Ca2+]i to MNs death is not clear though these
processes have been mostly credited to mitochondrial
Ca2+ accumulation or glutamate excitotoxicity. Whether
the change in ΔΨm is simply an inevitable consequence
of an unusually enormous Ca2+ load or there is other
downstream pathway contributing to glutamate response
is not known yet, however depolarisation of ΔΨm is one
consequences of it. Data also suggested the role for other
factor in addition to Ca2+ such as nitric oxide synthase
(NOS) inhibitors. Results also suggest that mitochondrial
damage arbitrated at least in part by Ca2+ induced MPTP
opening and may contribute to surge of neighbouring cell
activation. In conclusion, we believe that two of the most
important features for MNs in ALS are: (i) low buffercapacity generates exceptionally large Ca2+ domains, but
not in case of serious end stage ALS like symptoms and
(ii) in ALS vulnerable MNs buffering capacity critically de-
pends upon the domain size of mitochondria and ER.
Therefore, we proposed a model where a portion of MN
mitochondria interacts with areas of high [Ca2+] around
influx sites due to low buffering induced excitotoxicity
shown in Figure 2C.
Another proposed factor for calcium disregulation
could be an ALS-related immune response targeted at
voltage-dependent calcium channels (VDCC), where a
disruption of Ca2+ homeostasis results from compromised
voltage-dependent calcium influx [129]. Furthermore,
synaptic glutamate transport is also believed to be involved
in other forms of ALS and related MN neurodegeneration.
In cell-culture, limited protection was achieved by treat-
ment with nifedipine, implicating Ca2+ entry through
voltage-gated Ca2+ channels, in addition to glutamate
receptors, in mediating the toxicity of mtSOD1 in MNs.
The crucial role of Ca2+-permeable AMPAR was further
emphasized by cross-breeding of Tg SOD1 mice with
mice that exhibited markedly reduced Ca2+ permeability
of AMPA/kainate receptors, due to GluR2 overexpres-
sion [45,126]. Finally, impaired mitochondrial calcium
transport capacity in mtSOD1 mice may play an im-
portant role. Firstly, it links mitochondrial dysfunction
to glutamate excitotoxicity and secondly, elevation
of [Ca2+]c concentrations in neurons compromises
mitochondrial integrity and function by inducing en-
hanced production of ROS from mitochondria [130];
Figure 2C.
Glutamate transmission and excitotoxicity
Glutamate is known as the predominant excitatory neuro-
transmitter in the CNS acting at both ionotropic and
metabotropic receptors. It is synthesized and stowed in
synaptic nerve components and released in response to
depolarization of the neuron. Excessive glutamate expos-
ure is toxic to neurons via glutamate-triggered Ca2+ influx
[73,131]. Several lines of proof implicate increases in glu-
tamate neurotransmission and glutamate-triggered Ca2+
entry as significant ALS risk-factors. Increased extracellu-
lar glutamate levels result from reduced glial glutamate
uptake due to oxidative damage to excitatory amino acid
transporter 2 (EAAT2) or by aberrations in its production.
Increased glutamate levels in the cerebrospinal fluid (CSF)
of a subset of ALS patients have been shown by many
groups. The elevation of this glutamate level may be
attributed to deficient glutamate transporter capacity
(loss of EAAT2 function), as low levels of the transport
protein have been found in some post mortem ALS brains
[66,73,132]. Furthermore, glutamate uptake inhibitors
causes selective MN damage in organotypic slices [66]
and in dissociated spinal cord culture [133], suggesting
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to the MN damage seen in the ALS disease. The leading
argument for a role of glutamate excitotoxicity in ALS is
the efficacy of FDA approved drug riluzole, the lone
drug which proved effective against disease progression
in patients and has anti-excitotoxic properties. It was
shown that riluzole inhibits the release of glutamate
through the inactivation of voltage-dependent Na+
channels on glutamatergic nerve terminals as well as to
activate a G-protein-dependent signal transduction
cascades.
In-vivo evidence for a possible role of GluR1-4 (AMPA
receptor subunits) in ALS comes from several studies.
Transgenic mice lacking GluR2 (GluR2 subunit is a com-
ponent in the AMPA receptor complex, which renders
them particularly impermeable to calcium) do not hurt
from MN disease. This suggests that a low GluR2 level is
a modifier of MN degeneration rather than being sufficient
to cause ALS [134]. Furthermore, glutamate excitotoxicity
in sALS is caused by a selective loss of astrocytic glutamate
transporter-1 (GLT-1) and is reproduced in mice by
knockout of GLT-1, a homologue of EAAT-2 [135].
Oral administration of glutamate inhibitors prolonged
the life span of SOD1G93A mice [136]. Further studies
have pointed to the significance of GluR2 in neuronal
survival, in which alterations in RNA editing at the Q/R
site lead to the generation of a lethal phenotype involving
seizure and acute neurodegeneration [137]. Furthermore,
Glu2-N overexpression induces a progressive decline in
the function of spinal cord, most likely due to the long-
onset degeneration of spinal MNs [138].
Mechanism underlying mitochondria-ER Ca2+ stores
coupling
Diverse microdoamin intracellular pools contribute in
causing Ca2+ signals in neuronal cells and in shaping their
spatio-temporal patterns and cell fate. Kinetic and “hot
spot” hypothesis of mitochondria, different channels with
distinct properties and highly defined expression patterns
on ER are all capable of regulating [Ca2+]i in many systems
[139,140]. In an attempt to understand more about the
Ca2+ metabolism of hypoglossal MNs, Jaiswal and col-
leagues studied the role of the ER in Ca2+ handling where
it was shown that the ER in MNs retained a comparatively
lower quantity of calcium than mitochondria after [Ca2+]i
elevation, indicating a relative inability to sequester Ca2+
in the MNs of SOD1G93A mice as compared to WT letter-
mates. These results indicate that the conventional Ca2+
storing function of mitochondria is dominating over ER
Ca2+ accumulation in these MNs. These results are in
good agreement with the “hotspot” hypothesis that sug-
gests that mitochondria preferentially accumulate Ca2+ at
microdomains of elevated Ca2+concentration ([Ca2+]i),
predominantly near ER Ca2+ release sites and other Ca2+channels. Accordingly, mitochondria can affect both Ca2+
release from the ER and capacitative Ca2+ entry across the
plasma membrane, thereby shaping the size and duration
of the intracellular Ca2+ signal in MNs of WT and
SOD1G93A mice. These events determined by the Ca2+
sensitivity of the Ca2+ channels and capability of mito-
chondria to remove Ca2+ from the subcellular micro-
domain at the opening of the ion channel. This effect
has been confirmed in-vitro, but the condition appears
markedly different in various cell models [141,142].
This indicates that several modulatory mechanisms
occur, many of which still await reasonable clarifica-
tion at cellular and molecular level. As discussed
above, vast evidence supports the notion that the mea-
sured high degree of Ca2+ accumulation of MNs mito-
chondria in-situ mainly influenced by the vicinity of
mitochondria to the ion channels through which Ca2+
enters the cytosol. A fundamental, but still unanswered,
question is the precise mechanism by which stochastic
versus specific localization of Ca2+ influx occur and the
amount to which mitochondrial function differs within
different cell types, are critical quest in the field of ALS
research.
Mitochondrial dysfunction, Ca2+ homeostasis and ALS: a
multifactorial disease mechanism
The Ca2+-dependent signaling mechanisms that result in
the enhanced vulnerability of MNs in ALS disease and as-
sociated mouse models are also critical for normal cellular
function. Earlier studies suggest that unrestrained Ca2+
entry compounded with an inability to sequester this cal-
cium leads to the degeneration of mitochondria in the
MNs of the mouse model of ALS [29,31]. In other MNs
types have a low Ca2+-buffering capacity because of small
concentrations of Ca2+-buffering proteins and a high
quantity of Ca2+-permeable AMPAR [126,143-146].
These two properties appear to be specific to MNs and
are possibly vital for their normal function. However,
this increased sensitivity to calcium also means that
MNs are more easily over stimulated by glutamate and
astounded by Ca2+. It is unknown whether Ca2+ dependent
pathways are different in MNs. More recently, focus was
shifted to the role of mitochondria as an effective regulator
of [Ca2+]i signals [147,148]. The use of mitochondria-
targeted Ca2+ probes reveals a fast, intense surge in free
intra-mitochondrial Ca2+ upon cellular stimulation. In-
creased Ca2+ uptake by mitochondria leads to up-regulation
of the enzymes activity in oxidative metabolism, result-
ing in cell-specific metabolic changes [149-151]. This
hypothesis is further strengthened by the appearance of
abnormalities in mitochondrial ultrastructure and vacu-
oles formation resulted from degenerating mitochondria
found in post mortem samples of ALS [28-31]. Even
though the precise molecular mechanism is still not known,
Jaiswal Molecular and Cellular Therapies 2014, 2:26 Page 9 of 15
http://www.molcelltherapies.com/content/2/1/26we hypothesize that MN vulnerability in ALS is a outcome
of physiological features, mainly highly specialized Ca2+
surroundings that are required for appropriate neuronal
function, uninterrupted activity-dependent mitochondria-
ER Ca2+ cycling and the leading role of mitochondria in
buffering Ca2+ transients.
In vulnerable MNs, low instrinsic cytosolic Ca2+ buffering
requires that mitochondria play the dominant role in the
regulation of [Ca2+]i transients; even during small cytosolic
Ca2+ increases, mitochondria are known to take up more
than 50% of intracellular Ca2+. Outsized and enduring Ca2+
microdomains around Ca2+ influx sites increase the danger
of toxic Ca2+ buildups and a successive activation of Ca2+
dependent neurodegenerative pathways under excitotoxic
conditions. Excitotoxicity associated with these influx
domains is primarily suppressed by mitochondrial con-
tributions, rather than ER Ca2+ uptake [36,94,99]. The
prominent role of mitochondria in regulating adequate
Ca2+ loads in MNs has significant implications for
pathological conditions such as in ALS. First, the
quantity of Ca2+ taken up by the mitochondria is greater
in MNs than in many others cell types and therefore
MN mitochondria are more susceptible to Ca2+ mediated
damage, such as ROS generation [37,46,152]. Second, our
experiments provide indication that the restriction of
cytosolic Ca2+ to non-pathoological levels is determined
by intact Ca2+ uptake into mitochondria. Hence, when
mitochondrial Ca2+ uptake is disturbed as seen by low
Ca2+ uptake in SOD1G93A MNs compare to WT, MNs
are directly endangered by elevated Ca2+ levels, espe-
cially during high-frequency, repetitive Ca2+ oscillations.
The reduced capability to limit Ca2+ transient ampli-
tudes in the cytosol, particularly in local microdomains
of extraordinary Ca2+ influx when mitochondria are
depolarised, heightens the hazard of initiating Ca2+
dependent neurodegenerative pathways leading to cell
demise.
Combining the lessons learned from multiple animal
and cell culture models of ALS, the central insight is that
mitochondrial dysfunction and Ca2+ homeostasis [152,153]
are strong contributors to the selective vulnerability of
MNs. Considering the association and significance of
mitochondrial dysfunction and Ca2+ homeostasis, we
postulate that MN possess large number of voltage and
ligand gated Ca2+ channels that, when activated, cause
rapid Ca2+ influx. Since cytoplasmic Ca2+ buffering is
relatively weak in these cell types, significant demand is
placed on MN mitochondria. If the mitochondria are
already damaged or weakened, this results in mitochon-
drial Ca2+ overload and ROS production and in some
cases prone for infection [154]. Furthermore, long-lasting
ΔΨm depolarisation due to Ca
2+ entry can be a basis for
the release of pro-apoptotic proteins and activate enzymes
involved in apoptotic pathways [155,156].Multidrug therapies in ALS: where should we focus for
the treatment?
Even though scientific discoveries are speeding up with
an exceptional pace and years of experimentation using
cell cultures, mice and rat made Tg for human mtSOD1
has yielded precious data about the mechanisms that
underlie ALS as well as suggestions for therapy, to date
approaximately ~50 clinical trials have failed and ended
with disappointment and frustration. The main cause for
the failure to translate experimentation in animals to
therapies for patients is that there are too many com-
pounds that increase life span in mice and rats, but fail
to improve human patients condition. To increase the
chances of success for future clinical trials we might
consider the fact that ALS is not simply a multifactorial
disease but also a multisystemic disease that is the con-
sequence of a complex neurotoxic mechanism that in-
volves molecular and cellular cross-talk between MNs,
glia and astrocytes. Prelinical trials have not yet resulted
in favorable outcomes, due to the fact that data are gen-
erally collected in animals of the identical age and with
the same mutation expressed in a homogeneous genetic
background whereas the age of beginning of disease, the
progression and the severity of ALS in human patients
are heterogeneous, signifying that possible genetic risk
factors and modifying causes exist for sALS and certain
drugs are effective only if given before onset of the disease
[157-159]. In addition, the trial suffers from the deficiency
of presumed negative clinical data set, which is different
from the null result (i.e. data that do not affect the out-
come). Interestingly, in most of the clinical trials, a subset
of the patient population showed better condition with
the possibility that each clinical trial has been successful
within only a select subset of the patient population [158].
It is also important to keep in mind that ALS is a
multifactorial disease, and it might be unrealistic to envi-
sion that one drug will have a broad spectrum of efficacy
on pathologies that are widespread and, at times unre-
lated. In view of recent findings of a non-cell-autonomous
demise of MNs [47,48], design of multi drug combination
therapies should be targeted at the intersection of various
aspects of this cascade, rather than a single-drug cure
[157,158]. We suggest that the forthcoming clinical trials
should include combinatorial studies, and that patients
who display progress in their condition should not be con-
sidered as ‘outliers’, because they might indeed represent
the target population, especially for the drugs tested [157].
Until now animal studies have shown that multi-drug
combination therapies and the method of delivery of a
drug is also often have synergistic effects in ALS, for ex-
ample, riluzole administered with melatonin and vitamine
E (inhibits Na+-current activation and the apoptotic cas-
cade), minocycline administered with creatine (inhibits
microglia activation and the apoptotic signaling cascade),
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in MNs through viral vectors [111-119,136,158-163]. A
substitute to pharmacological cures, the latest develop-
ments in stem-cell therapy might offer possibilities for
neural grafting in patients with ALS [114,158,164]. The
identification and characterization of early detection
markers in ALS, and the establishment of dependable bio-
markers for disease progression in a select set of clinical
trials studies on blood, plasma and cerebrospinal fluid
(CSF), obtained from patients and control subjects bounds
to improved improved clinical trials [165]. The lessons
learned from a decade of research using the mtSOD1
animal model might help scientists in finding cures for
neurodegeneration where single-drug treatments have
confirmed insufficient for effective treatment of ALS.
Conclusions
In spite of rigourous research for years there are several
important questions still unanswered; these include: (a)
does the expression of mtSOD1 at physiological levels
causes morphological and structural abnormalities of
mitochondrial assembly and its calcium buffering capacity?
(b) At pathophysiological levels, does the mitochondria-ER
and EMRCC Ca2+ sequestration source specificity and
spatiotemporal properties of [Ca2+]i signaling varies at sub
cellular level in and around microdomain? (c) In the pres-
ence of mtSOD1 gene, what are the consequences of alter-
ations in mitochondrial function on Ca2+ homeostasis and
ERMCC? Numerous developments and improvements in
visualization of diseased MNs and spatiotemporal reso-
lution of mitochondria-ER calcium signaling cascades
have the potential to bring novel insights. MN possess
numerous Ca2+ channels that cause rapid Ca2+ influx
because of comparatively weak [Ca2+]i buffering, results
in mitochondrial Ca2+ overload and strong ROS generation
in mtSOD1 Mice. Further studies of ER-mitochondria cal-
cium cycle (ERMCC) with targeted calcium probes show a
rapid and dramatic increase in free intra mitochondrial
and ER calcium. The defects in mitochondrial assembly
and vacuoles derived from defective mitochondria found
in post mortem ALS patients further support the sugges-
tion. Design of novel antioxidant strategies to selectively
target the oxidative stress and redox imbalance is the
other evenue need to be explored. Furthermore, check
on selective loss of MNs causing the discharge of pro-
apoptotic proteins which activate enzymes leads to
activation of apoptotic pathways and apoptotic cells
observed in MNs of ALS is beneficial. Dysregulation
between mitochondria-ER and ERMCC are well known
features and therapeutic drugs aiming to stabilize these
cycles reduce ROS and oxidative stress and may be effect-
ive in wide range of MN diseases. Another nice direction
would be to develop so called “smart drugs” and “com-
bination therapies or multi drug therapies” which havemutifactorial imact on disease mechanism due to mulfac-
torial nature of ALS disease. Furthermore, it is hypothe-
sized that disrupted Ca2+ homeostasis and oxidative stress
induced ROS have a vital role in propagating injury by
increasing the excitability of MNs and by targeting
neighboring glia. Perhaps as a consequence, excitotoxicty
builds up with increased activity-dependent Ca2+ influx
and associated mitochondrial Ca2+ cycling. Given the
mitochondrial disturbances, Ca2+ buffering becomes in-
efficient and increase in cytosolic Ca2+ levels. Protective
options are to elevate the resistance of MNs to high
intracellular Ca2+ concentrations by inducing defense
mechanism and/or to inhibit the downstream apoptotic
and death cycle pathways activated by increased intracellu-
lar Ca2+ concentrations. However, severely impaired MNs
are not amendable to taking functional advantage of neur-
onal protection in ALS.
Therefore perhaps we should focus on new tools such
as recently discovered genes that cause ALS and induced
pluripotent stem cells taken from ALS patients and de-
rived into MNs to identify potential cytosolic pathways
and barriers that could lead to MN degeneration in ALS.
Forthcoming studies will hopefully add to the understand-
ing of why these processes preferentially damage MNs
and the role non-cell autonomous cell death might play.
In conclusion, data indicates that ALS is a multifactorial
disease and therefore a combined therapeutic interference
(combination therapy) with many facets of target site both
at the MNs and glial cells will be most likely essential for
survival of ALS patients. While keeping in mind the previ-
ous failures in clinical trials for ALS, further studies in this
direction to better understand the pathogenesis of cell
death in ALS and targeted therapy therefore will be of
great interest.
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